Belzutifan as the first-line treatment for a challenging von Hippel-Lindau–related retinal hemangioblastoma: successful treatment of a case and review of the literature
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0008-4182
-
Container-title:Canadian Journal of Ophthalmology
-
language:en
-
Short-container-title:Canadian Journal of Ophthalmology
Author:
Aykut AslanORCID,
Else TobiasORCID,
Demirci Hakan
Reference11 articles.
1. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression;Keith;Nat Rev Cancer,2011
2. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease;Jonasch;N Engl J Med,2021
3. Two cases of von Hippel–Lindau syndrome-associated retinal hemangioblastoma treated with belzutifan;Grimes;Retin Cases Brief Rep,2024
4. Successful treatment response of a juxtapapillary retinal capillary hemangioblastoma due to von Hippel–Lindau with Belzutifan in a pediatric patient;Mustafi;Retina,2024
5. Cotton CC, Chandrabhatla AS, Andrews PH, Purrow BW, Shildkrot YE. Belzutifan for treatment of giant retinal hemangioblastoma with extrascleral extension associated with von Hippel–Lindau syndrome [e-pub ahead of print]. Retin Cases Brief Rep. doi:10.1097/ICB.0000000000001516, accessed 1 Feb, 2024.